AR009990A1 - ORTHOS-SULFONAMIDE HETEROARYL ACIDS BICYCLIC HYDROXAMICS AS MATRIX AND TACE METALOPROTEINASE INHIBITORS, USE OF SUCH COMPOUNDS TO PREPARE MEDICINES, AND CONTAINING PHARMACEUTICAL COMPOSITIONS - Google Patents

ORTHOS-SULFONAMIDE HETEROARYL ACIDS BICYCLIC HYDROXAMICS AS MATRIX AND TACE METALOPROTEINASE INHIBITORS, USE OF SUCH COMPOUNDS TO PREPARE MEDICINES, AND CONTAINING PHARMACEUTICAL COMPOSITIONS

Info

Publication number
AR009990A1
AR009990A1 ARP970104749A ARP970104749A AR009990A1 AR 009990 A1 AR009990 A1 AR 009990A1 AR P970104749 A ARP970104749 A AR P970104749A AR P970104749 A ARP970104749 A AR P970104749A AR 009990 A1 AR009990 A1 AR 009990A1
Authority
AR
Argentina
Prior art keywords
tace
disease
independently selected
membered heteroaryl
heteroaryl ring
Prior art date
Application number
ARP970104749A
Other languages
Spanish (es)
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of AR009990A1 publication Critical patent/AR009990A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Inhibidores no peptídicos de bajo peso molecular de las metaloproteinasas de matriz (por ejemplo, gelatinasas, estromelisinas y colagenasas) y de laenzima conversora de TNF - alfa (TACE, enzima de conversion de factor alfa de necrosis tumoral) que son utiles para el tratamiento de enfermedades en lascuales intervienen estas enzimas, tales como la artritirs, la metástasis y desarrollo de tumores, alangiogénesis, al ulceracion de tejidos, lacicatrizacion anormal de heridas, enfermedad periodontal, enfermedad osea, proteinuria, enfermedad de aneurisma aortico, pérdida degenerativa de cartílagoposterior a lesion traumática de las articulaciones, enfermedades desmielinizantes del sistema nervioso, rechazo de injertos,caquexia, anorexia,inflamacion, fiebre resistencia a la insulina, choque séptico, insuficiencia cardíaca congestiva, enfermedad inflamatoria del sistema nervioso central,enfermedad inflamatoria intestinal, infeccion por HIV, degeneracion macularasociada a la edad, retinopatía diabética, vitreorretinopatía proliferativa,retinopatía de la prematuridad, inflamacion ocular, queratocono, síndrome de Sjogren, miopía, tumores oculares, angiogénesis/ neovascularizacion ocular. Losácidos orto-sulfonamido arilhidroxámicos inhibidores de TACE y MMP están representados por la formula (I) en la cual la porcion de ácido hidroxámico yla porcion sulfonamido están unidas a los carbonos adyacentes del grupo A donde A es un anillo heteroarilo de 5 a 6 miembros con 1 a 3 heteroátomosindependientemente seleccionados entre N, O y S fusionado o un anillo heteroarilo de 5-6 miembros que tiene de 1 a 3 heteroátomos independientementeseleccionados entre N, O y S fusionado o un anillo heteroarilo de 5-6 miembros que tiene de 1 a 3 heteroátomos independientemente seleccionados entre N, O y SLow-molecular-weight, non-peptidic inhibitors of matrix metalloproteinases (eg, gelatinases, stromelysins, and collagenases) and TNF-alpha converting enzyme (TACE), which are useful for the treatment of Diseases in which these enzymes are involved, such as arthritis, metastasis and development of tumors, alangiogenesis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, proteinuria, aortic aneurysm disease, degenerative loss of cartilage after injury traumatic joints, demyelinating diseases of the nervous system, graft rejection, cachexia, anorexia, inflammation, insulin resistance fever, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease, HIV infection, degeneration age-related macularas, retin Diabetic Opathy, Proliferative Vitreoretinopathy, Retinopathy of Prematurity, Eye Inflammation, Keratoconus, Sjogren's Syndrome, Myopia, Ocular Tumors, Ocular Angiogenesis / Neovascularization. The ortho-sulfonamido arylhydroxamic acids inhibitors of TACE and MMP are represented by formula (I) in which the portion of hydroxamic acid and the portion of sulfonamido are attached to the adjacent carbons of group A where A is a 5-6 membered heteroaryl ring with 1 to 3 heteroatoms independently selected from fused N, O, and S or a 5-6 membered heteroaryl ring having 1 to 3 independently selected heteroatoms between fused N, O, and S, or a 5-6 membered heteroaryl ring having 1 to 3 heteroatoms independently selected from N, O and S

ARP970104749A 1996-10-16 1997-10-15 ORTHOS-SULFONAMIDE HETEROARYL ACIDS BICYCLIC HYDROXAMICS AS MATRIX AND TACE METALOPROTEINASE INHIBITORS, USE OF SUCH COMPOUNDS TO PREPARE MEDICINES, AND CONTAINING PHARMACEUTICAL COMPOSITIONS AR009990A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73200496A 1996-10-16 1996-10-16

Publications (1)

Publication Number Publication Date
AR009990A1 true AR009990A1 (en) 2000-05-17

Family

ID=24941797

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104749A AR009990A1 (en) 1996-10-16 1997-10-15 ORTHOS-SULFONAMIDE HETEROARYL ACIDS BICYCLIC HYDROXAMICS AS MATRIX AND TACE METALOPROTEINASE INHIBITORS, USE OF SUCH COMPOUNDS TO PREPARE MEDICINES, AND CONTAINING PHARMACEUTICAL COMPOSITIONS

Country Status (4)

Country Link
AR (1) AR009990A1 (en)
AU (1) AU743901B2 (en)
WO (1) WO1998016514A1 (en)
ZA (1) ZA979235B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548524B2 (en) * 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
WO1998016520A1 (en) * 1996-10-16 1998-04-23 American Cyanamid Company The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
ATE242768T1 (en) * 1997-10-06 2003-06-15 Wyeth Corp PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
AR035311A1 (en) * 1999-01-27 2004-05-12 Wyeth Corp HYDROXAMIC ACID DERIVATIVES CONTAINING ALQUINYL, AS INHIBITORS OF THE METALLOPROTEINAS OF MATRIX AND THE TACE, PHARMACEUTICAL COMPOSITION AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AR022424A1 (en) * 1999-01-27 2002-09-04 American Cyanamid Co COMPOUNDS DERIVED FROM ACIDS ORTOSULFONAMIDO ACETYLENE AND HYDROXAMIC HYDROXAMIC HYDROARAMYL AMID OF PHOSPHINIC ACID AS INHIBITORS TACE, COMPOSITION PHARMACEUTICAL THAT UNDERSTANDS AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICATION
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
WO2001062742A1 (en) 2000-02-21 2001-08-30 Astrazeneca Ab Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
WO2001062751A1 (en) * 2000-02-21 2001-08-30 Astrazeneca Ab Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
AR027943A1 (en) * 2000-02-25 2003-04-16 Wyeth Corp ARIL HYDROXAMIC ORTO-SULPHONAMIDE ACIDS AS MATRIX METALOPROTEINASE INHIBITORS AND PREPARATION OF THE SAME
US6465508B1 (en) 2000-02-25 2002-10-15 Wyeth Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
WO2001082911A2 (en) * 2000-04-28 2001-11-08 Gerolymatos P N Sa TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
US6436629B1 (en) 2000-10-27 2002-08-20 The Regents Of The University Of California Modulating angiogenesis
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
MXPA04002537A (en) 2001-10-12 2004-05-31 Warner Lambert Co Alkyne matrix metalloproteinase inhibitors.
WO2003037865A1 (en) * 2001-10-31 2003-05-08 Morphochem Aktiengesellschaft für kombinatorische Chemie Novel anticancer compounds
CA2464727A1 (en) 2001-11-01 2003-05-08 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
MXPA05001642A (en) * 2002-08-13 2005-04-25 Warner Lambert Co 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors.
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
TW200418825A (en) 2002-12-16 2004-10-01 Hoffmann La Roche Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives
WO2005021489A2 (en) 2002-12-23 2005-03-10 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
WO2006117660A2 (en) * 2005-05-04 2006-11-09 Clio Pharmaceutical Corporation Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins
JP5588339B2 (en) * 2007-06-25 2014-09-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング New chemical compounds
JP2012513464A (en) * 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Phosphodiesterase inhibitors and uses thereof
FR2947270B1 (en) 2009-06-30 2011-08-26 Galderma Res & Dev NOVEL BENZENE-SULFONAMIDE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND THEIR USE IN MEDICINE AND COSMETICS
FR2947268B1 (en) 2009-06-30 2011-08-26 Galderma Res & Dev NOVEL BENZENE-SULFONAMIDE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND THEIR USE IN MEDICINE AND COSMETICS
WO2011146591A1 (en) 2010-05-19 2011-11-24 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US20140275108A1 (en) 2013-03-15 2014-09-18 Galderma Research & Development Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Anti amphiregulin antibodies, compositions comprising same and uses thereof
US20190008828A1 (en) 2015-12-28 2019-01-10 The U.S.A., As Represented By The Secretary Department Of Health And Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
ES2695533T3 (en) 2016-02-01 2019-01-08 Galderma Res & Dev Benzenesulfonamide compounds, method for their synthesis and use in medicine and cosmetics
BR112021006407A8 (en) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med use of egfr inhibitors for keratoderms

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
WO1998016520A1 (en) * 1996-10-16 1998-04-23 American Cyanamid Company The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors

Also Published As

Publication number Publication date
AU4980697A (en) 1998-05-11
WO1998016514A1 (en) 1998-04-23
AU743901B2 (en) 2002-02-07
ZA979235B (en) 1999-04-15

Similar Documents

Publication Publication Date Title
AR009990A1 (en) ORTHOS-SULFONAMIDE HETEROARYL ACIDS BICYCLIC HYDROXAMICS AS MATRIX AND TACE METALOPROTEINASE INHIBITORS, USE OF SUCH COMPOUNDS TO PREPARE MEDICINES, AND CONTAINING PHARMACEUTICAL COMPOSITIONS
AR008677A1 (en) ORTHO-SULFONAMIDE HETEROARIL HYDROXAMIC ACIDS AS MATRIX METALPROTEINASE INHIBITORS, USE OF SUCH COMPOUNDS TO PREPARE MEDICINES, AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
AR008676A1 (en) HYDROSAMIC BETA-SULFONAMIDE ACIDS AS MATRIX METALOPROTEINASE INHIBITORS AND TACE, USE OF THEM IN PREPARATION OF A MEDICINAL PRODUCT AND A PHARMACEUTICAL COMPOSITION THAT CONTAIN THEM
AR009382A1 (en) DERIVATIVES OF ORTHO-SULFONAMIDE ACIDS ARYL HYDROXAMICS AS MATRIX METALOPROTEINASE INHIBITORS AND TACE, COMPOSITIONS THAT CONTAIN THEM AND USE THEMSELVES FOR THE PREPARATION OF A MEDICINAL PRODUCT.
RU2324684C2 (en) Pyrimidine derivatives
DK0871439T3 (en) Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
HUP9902092A2 (en) Metalloproteinase inhibitor benzenesulfonamide derivatives, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
NO20021728D0 (en) Pyrimidine derivatives
BR9813651A (en) Antipicornoviral compounds and methods for their use and preparation
EA200600975A1 (en) CONDENSED HETEROCYCLIC COMPOUNDS APPLICABLE FOR THE TREATMENT OF OBESITY AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM
EA200601194A1 (en) NEW DERIVATIVES OF BENZOFURANE USED FOR THE PREVENTION OR TREATMENT OF DISTURBANCES ASSOCIATED WITH 5-HT-RECEPTOR
ES2038172T3 (en) PROCEDURE FOR PREPARING HETERO CYCLIC CARBOXAMIDES.
FR2800735B1 (en) NOVEL ARALKYL-1,2-DIAMINES HAVING CALCIMIMETIC ACTIVITY AND THEIR METHOD OF PREPARATION
AR022423A1 (en) COMPOUNDS DERIVED FROM ACIDS 2,3,4,5-TETRAHIDRO-1H- [1,4] BENZODIAZEPINA-3-HYDROXAMICS, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
MA28340A1 (en) 7-AMINO-4-QUINOLONE-3-CARBOXYLIC ACID DERIVATIVES SUBSTITUTED WITH CYCLOALKYL GROUP, METHOD FOR PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS
SE8406201L (en) penicillanic acid
SE8700714D0 (en) USE OF SUBSTITUTED 4-PHENYL-4-OXO-2-BUTENIC ACID DERIVATIVES FOR THE PREPARATION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF DISEASES IN THE FOOD CHANNEL AND AS ANTIULCEROST MEDICINE
AR041481A1 (en) ARILPROPIONIC-OXAZOL ACID DERIVATIVES AND ITS USE AS PPAR AGONISTS
BR9909267A (en) C11 oxymyl and hydroxylamino prostaglandins useful as medications
AR022405A1 (en) DERIVATIVES OF PYROGLUTAMIC ACID AND RELATED COMPOUNDS THAT INHIBIT THE ADHESION OF LEUCOCITS INTERMEDIATED BY VLA-4, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE MANUFACTURE OF AGENTS AND MEDICINES
IL166103A0 (en) Pyrrolidine derivatives and their use
NO155135C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 3-AMINO-1-BENZOXEPINE DERIVATIVES.
ATE73807T1 (en) NEW BENZIMIDAZOLES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL PRODUCTS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS.
KR102042411B1 (en) A composition comprising decursin derivative for preventing or treating of tuberculosis
FR2375225A1 (en) NEW BASICALLY SUBSTITUTED O-PROPYLOXIMES, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS